According to a post-effective amendment filed earlier today, biotech Anthera Pharmaceuticals now plans to raise $42 million by offering 6 million shares (6.9 million with the overallotment) at $7 per share instead of the previously expected 4.6 million shares at $13-$15. Venture backers have stepped up participation, indicating they will purchase almost 37% of the deal, or 2.2 million shares. Deutsche Bank is the lead underwriter on the deal, which is expected to price on Monday, Mar. 1 after the market close.
